TY - JOUR
T1 - Fatty acid composition and fatty acid binding protein expression in the postmortem frontal cortex of patients with schizophrenia
T2 - A case-control study
AU - Hamazaki, Kei
AU - Maekawa, Motoko
AU - Toyota, Tomoko
AU - Iwayama, Yoshimi
AU - Dean, Brian
AU - Hamazaki, Tomohito
AU - Yoshikawa, Takeo
N1 - Funding Information:
This work was supported by a Grant-in-Aid for Scientific Research (C) ( 25461726 ), Japan. BD is a National Health and Medical Research Council Senior Research Fellow ( APP1002240 ). This work was supported in part by the Victorian Government's Operational Infrastructure Support . The funding sources had no role in the study design; the collection, analysis, and interpretation of data; writing the report; or the decision to submit the paper for publication.
Funding Information:
K.H. received research support from an Intramural Research Grant for Neurological and Psychiatric Disorders from the National Center of Neurology and Psychiatry and a grant from the Japan Society for the Promotion of Science ; consultant fees from Polyene Project, Inc.; and scholarship donations from Otsuka Pharmaceutical Co., Ltd. T.H. has received lecture fees from Takeda Pharmaceutical Co., Ltd. and travel expenses from Aker BioMarine. M.M., T.T., Y.I., B.D., and T.Y. reported no conflicts of interest.
Funding Information:
This work was supported by a Grant-in-Aid for Scientific Research (C) (25461726), Japan. BD is a National Health and Medical Research Council Senior Research Fellow (APP1002240). This work was supported in part by the Victorian Government''s Operational Infrastructure Support. The funding sources had no role in the study design; the collection, analysis, and interpretation of data; writing the report; or the decision to submit the paper for publication. We are grateful to Ms. Shizuko Takebe (University of Toyama) for her technical assistance. We thank Drs. Ken-ichi Moto and Toshihide Kobayashi (RIKEN Lipid Biology Laboratory) for their technical advice. The Victorian Brain Bank Network is supported by the Florey Institute for Neuroscience and Mental Health, Alfred Hospital, the Victorian Forensic Institute of Medicine, and the University of Melbourne, and is funded by Australia''s National Health & Medical Research Council, the Helen Macpherson Smith Trust, and Parkinson''s Victoria and Perpetual Philanthropic Services.
Funding Information:
We are grateful to Ms. Shizuko Takebe (University of Toyama) for her technical assistance. We thank Drs. Ken-ichi Moto and Toshihide Kobayashi (RIKEN Lipid Biology Laboratory) for their technical advice. The Victorian Brain Bank Network is supported by the Florey Institute for Neuroscience and Mental Health, Alfred Hospital, the Victorian Forensic Institute of Medicine, and the University of Melbourne, and is funded by Australia's National Health & Medical Research Council , the Helen Macpherson Smith Trust , and Parkinson's Victoria and Perpetual Philanthropic Services .
Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Background: Abnormal levels of n-polyunsaturated fatty acids (PUFAs), particularly docosahexaenoic acid (DHA), have been found in the postmortem frontal cortex, particularly the orbitofrontal cortex, of patients with schizophrenia. Altered mRNA expression of fatty acid binding protein (FABP) 5 and FABP7 has likewise been reported. Methods: This study investigated whether PUFAs in the frontal cortex [Brodmann area (BA) 8] and mRNA expression of FABP3, 5, and 7 were different between patients with schizophrenia (= 95) and unaffected controls (= 93). Results: In contrast to previous studies, no significant differences were found in DHA between the groups. Although arachidonic acid (AA) levels were significantly decreased in the schizophrenia group, no association was found between AA and schizophrenia on logistic regression analysis. Only FABP3 expression was significantly lower in the schizophrenia group than in the control group. Significant inverse associations were seen between only two saturated fatty acids, behenic acid and lignoceric acid, and FABP3 expression. Conclusions: We found no evidence that major PUFA levels in BA8 are involved in the etiology of schizophrenia. Although FABP3 expression was not correlated with any of the major PUFAs, it might play a novel role in the pathology of BA8 in a subset of patients with schizophrenia.
AB - Background: Abnormal levels of n-polyunsaturated fatty acids (PUFAs), particularly docosahexaenoic acid (DHA), have been found in the postmortem frontal cortex, particularly the orbitofrontal cortex, of patients with schizophrenia. Altered mRNA expression of fatty acid binding protein (FABP) 5 and FABP7 has likewise been reported. Methods: This study investigated whether PUFAs in the frontal cortex [Brodmann area (BA) 8] and mRNA expression of FABP3, 5, and 7 were different between patients with schizophrenia (= 95) and unaffected controls (= 93). Results: In contrast to previous studies, no significant differences were found in DHA between the groups. Although arachidonic acid (AA) levels were significantly decreased in the schizophrenia group, no association was found between AA and schizophrenia on logistic regression analysis. Only FABP3 expression was significantly lower in the schizophrenia group than in the control group. Significant inverse associations were seen between only two saturated fatty acids, behenic acid and lignoceric acid, and FABP3 expression. Conclusions: We found no evidence that major PUFA levels in BA8 are involved in the etiology of schizophrenia. Although FABP3 expression was not correlated with any of the major PUFAs, it might play a novel role in the pathology of BA8 in a subset of patients with schizophrenia.
KW - Fatty acid binding protein
KW - Frontal cortex
KW - Polyunsaturated fatty acids
KW - Postmortem brain
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=84958116269&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958116269&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2016.01.014
DO - 10.1016/j.schres.2016.01.014
M3 - Article
C2 - 26792082
AN - SCOPUS:84958116269
SN - 0920-9964
VL - 171
SP - 225
EP - 232
JO - Schizophrenia Research
JF - Schizophrenia Research
IS - 1-3
ER -